7.2. pre- post-operative radiotherapy muscle-invasive bladder cancer. 7.2.1. post-operative radiotherapy given high rates local-regional failure rc patients locally-advanced (pt3–4) bc, estimated ~30%, well high risk distant failure poor survival patients, interest adjuvant therapies address risk local distant disease. data adjuvant rt rc limited prospective studies needed, recent phase ii trial compared adjuvant sequential chemotherapy radiation vs. adjuvant chemotherapy alone 120 patients locally-advanced disease negative margins rc (with one risk factors: ≥ pt3b, grade 3, node-positive), study population 53% uc 47% scc. addition adjuvant rt chemotherapy alone associated statistically significant improvement local relapse-free survival (at 2 years 96% vs. 69% favouring addition rt). disease-free survival os also favoured addition rt, differences statistically significant study powered endpoints. late-grade ≥ 3 gi toxicity chemoradiation arm low (7% patients) . 2019 systematic review evaluating efficacy adjuvant radiation bc utuc found clear benefit adjuvant radiation following radical surgery (e.g., cystectomy), although combination adjuvant radiation chemotherapy may beneficial locally-advanced disease . adjuvant radiation might considered patients pt3/pt4 pn0–2 urothelial bc following rc, although approach evaluated limited number studies without conclusive data demonstrating improvements os. radiation fields encompass areas risk harbouring residual microscopic disease based pathologic findings surgery may include cystectomy bed pelvic lns. doses range 45 50.4 gy may considered. phase ii trial 72 patients showed dose 50.4 radiotherapy gy used acceptable toxicity high rate local control . small retrospective study 25 patients (median age 64 years) evaluated acute late toxicity moderate doses pelvic rt (range, 45–50.4 gy). median follow-up 10.4 months authors concluded orthotopic ileal neobladders tolerate moderate radiation doses without significant induced morbidity. acute gi toxicity seen grade 1, four patients developed acute grade 2 toxicity; three treated nac . patients treated nac, may reasonable sandwich adjuvant radiation cycles adjuvant chemotherapy. safety efficacy concurrent radiosensitising chemotherapy adjuvant setting needs study. 7.2.2. pre-operative radiotherapy date, six rcts published investigating pre-operative rt, although several decades ago. largest trial, pre-operative rt dose 45 gy used, resulting significant increase pathological complete response (9% 34%) favour pre-operative rt, also prognostic factor survival . os data difficult interpret since chemotherapy used subset patients 50% patients (241/475) receive planned treatment excluded final analyses. two smaller studies using dose 20 gy showed small survival advantage ≥ t3 tumours . two small trials confirmed downstaging pre-operative rt . retrospective analysis 1,846 evaluable patients, 34 patients received rt prior orthotopic neobladder reconstruction. authors conclude following pelvic rt, neobladder possible highly selected patients statistically similar peri-operative complication rates compared patients receive prior rt. patient selection, oncologic factors (positive urethral margins, nodal involvement, extravascular disease) commonly technical factors (adhesions/difficult dissection, bleeding, urethral stricture) influencing conversion planned neobladder reconstruction . meta-analysis five rcts showed difference 5-year survival (or: 0.71, 95% ci: 0.48–1.06) favour pre-operative rt . however, meta-analysis potentially biased data largest trial patients given planned treatment. largest trial excluded analysis, became 0.94 (95% ci: 0.57–1.55), significant. recent rct, comparing pre-operative vs. post-operative rt rc (n = 100), showed comparable os, dfs complication rates . approximately half patients uc, half scc. general, older data limited able provide robust evidence base modern guideline recommendations. 7.2.3. local therapy (surgery radiotherapy) oligometastatic disease disease state may emerging role adding local therapy oligometastatic bladder cancer. oligometastatic status defined situation limited number metastatic sites. recent consensus, maximum three metastatic sites, either resectable amenable stereotactic therapy, proposed definition oligometastatic bladder cancer . studies tumour types (prostate cancer, colorectal cancer lung cancer) suggest possible survival benefit adding local therapy. bladder cancer, retrospective studies suggest potential survival benefit incorporating local therapy bladder (including radiation therapy chemotherapy alone) metastatic disease , employing metastasis-directed therapy. [324-327] favourable response systemic treatment proposed criterion selection patients metastasis-directed therapy . however, data oligometastatic disease limited prospective study bladder cancer patients needed. 7.2.4. summary evidence guidelines pre- post-operative radiotherapy summary evidenceleno contemporary data exists support pre-operative rt operable mibc increases survival.2apre-operative rt operable mibc, using dose 45–50 gy fractions 1.8–2 gy, results down-staging 4 6 weeks.2limited evidence supports safe use pre- post-operative rt case neobladder planned situ.3limited high-quality evidence supports use pre-operative rt decrease local recurrence mibc rc.3addition adjuvant rt chemotherapy associated improvement local relapse-free survival following cystectomy locally-advanced bladder cancer (pt3b–4, node-positive).2athere randomised trials showing effect local therapy oligometastastic bladder cancer.1retrospective case series show survival benefit additional local therapy (to primary sites metastases) oligometastatic bladder cancer.3 recommendationsstrength ratingdo offer pre-operative radiotherapy (rt) operable muscle-invasive bladder cancer since result down-staging, improve survival.strongdo offer pre-operative rt subsequent radical cystectomy (rc) urinary diversion planned.strongconsider offering adjuvant rt addition chemotherapy following rc, based pathologic risk (pt3b–4 positive nodes positive margins).weakinform patients oligometastatic disease local therapy treatment options. patients carefully selected treatment fully informed potential benefits harms different treatment modalities well fact definitive evidence supporting local therapy inoligometastatic disease.weak